Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cryoport, Inc.

NASDAQ: CYRX · Life Sciences · 4 alerts · CIK 1124524

Share price
$19.80Close, Nov 16
Market cap
$1B
Shares outstanding
50.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cryoport, Inc. filings on SEC EDGAR ↗

6:31 PM ET Form 4
Insider Selling

Cryoport CSO Mark W. Sawicki Sells $199K of Stock

Mark W. Sawicki, CSO, sold 10,000 shares of Cryoport, Inc. at $19.93 a share, worth $199K in total on Nov 10, 2026. Shares held after the trade: 92,356 (-9.8%).

Value
$199K
Shares
10,000
Price
$19.93
Role
CSO
Holding change
-9.8%
Trade date
Nov 10, 2026
6:28 PM ET Form 4
Insider Selling

Cryoport Insider Daniel M. Hancock Sells $1.5M of Stock

Daniel M. Hancock sold 74,379 shares of Cryoport, Inc. at $20.21 a share, worth $1.5M in total on Nov 9, 2026. Shares held after the trade: 69,052 (-51.9%).

Value
$1.5M
Shares
74,379
Price
$20.21
Holding change
-51.9%
Trade date
Nov 9, 2026
5:09 PM ET 10-Q
Financial Results

Cryoport Q3 2026 Results: Net Loss of $10.9M, Loss Widens

Cryoport reported total revenue of $50.2 million for Q3 2026, a 13.5% increase compared to the same period in 2025. The company experienced a net loss of $10.9 million for the quarter, driven by increased operating costs and a $4.4 million other expense item, while maintaining a strong cash and short-term investment position of $393.1 million.

Key figure
Net loss $10.9M
4:33 PM ET 8-K
Financial Results

Cryoport Financial Results

Cryoport reported Q3 2026 revenue of $50.2 million, a 14% increase year-over-year, driven by 20% growth in commercial Cell and Gene Therapy revenue. The company achieved positive adjusted EBITDA of $1.1 million and raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.

Term
Q3 2026

“Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions.”

Jerrell Shelton, CEO of Cryoport

“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million.”

Jerrell Shelton, CEO of Cryoport

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.